Abstract：【Objective】To explore the application effect of dapagliflozin in the treatment of elderly patients with type 2 diabetic nephropathy complicated with hypertension. 【Methods】A total of 92 elderly patients with type 2 diabetic nephropathy complicated with hypertension who were treated in our hospital from March 2021 to March 2024 were selected and divided into the conventional group (given conventional treatment) and the dapagliflozin group (with conventional treatment plus dapagliflozin treatment) according to their medication conditions, with 46 cases in each group. The clinical indicators, renal function indicators, inflammatory indicators, oxidative stress response indicators and adverse reactions before and after treatment were compared between the two groups. 【Results】After treatment, the body mass index (BMI), diastolic blood pressure (DBP), systolic blood pressure (SBP), fasting blood glucose (FPG), glycated hemoglobin (HbA1c), total cholesterol (TC), and triglycerides (TG) of both groups were lower than those before treatment. However, there was no statistically significant difference in the estimated glomerular filtration rate (eGFR) between the two groups (P>0.05). After treatment, the urine microalbumin/creatinine ratio (UACR), homocysteine (Hcy), malondialdehyde (MDA), FPG, HbA1c, C-reactive protein (CRP), interleukin-17 (IL-17), and interleukin-8 (IL-8) levels in the dapagliflozin group were lower than those in the conventional group (P<0.05), while the superoxide dismutase (SOD) and glutathione peroxidase (GSH-Px) levels were higher than those in the conventional group (P<0.05). There was no statistically significant difference in the total incidence of adverse reactions between the two groups (P>0.05). 【Conclusion】The application effect of dapagliflozin in the treatment of elderly patients with type 2 diabetic nephropathy complicated with hypertension is significant. It can effectively reduce blood glucose and BMI, improve lipid indicators, protect renal function, reduce inflammatory response, and enhance antioxidant capacity, thereby improving the clinical indicators of patients from multiple aspects and improving their prognosis.
姜慧军. 达格列净在老年2型糖尿病肾病合并高血压患者治疗中的应用效果[J]. 医学临床研究, 2025, 42(7): 1213-1215.
JIANG Huijun. Application Effect of Dapagliflozin in Elderly Patients with Type 2 Diabetic Nephropathy Complicated by Hypertension. JOURNAL OF CLINICAL RESEARCH, 2025, 42(7): 1213-1215.
2025, Vol. 42 
